European Journal of Pediatrics

, 168:1315 | Cite as

Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age

  • DooIl Song
  • Yunku Yeo
  • KeeSoo Ha
  • GiYoung Jang
  • JungHwa LeeEmail author
  • KwangChul Lee
  • ChangSung Son
  • JooWon Lee
Original Paper



The clinical manifestations and risk factors for developing coronary artery abnormalities (CAA) in Kawasaki disease (KD) might differ depending on age.

Materials and methods

From January 2001 to July 2007, 161 patients with an age younger than 1 year (younger group) and 60 patients with an age older than 5 years (older group) were diagnosed with KD at the Korea University Medical Center. Their medical records were reviewed retrospectively and the two groups were compared in terms of a number of variables commonly associated with the development of CAA, including clinical manifestations and laboratory findings.


While the overall incidence of KD-associated CAA in our hospital was 6.7%, CAA developed in 20 (12.4%) of the younger group and ten (16.7%) of the older group, respectively. The CAA (+) cases of the younger group had a longer duration of total fever (9.1 ± 3.3 vs 6.3 ± 1.9 days, p = 0.002) and showed fewer diagnostic symptoms (3.0 ± 1.2 vs 4.3 ± 1.1, p < 0.001) than the CAA (−) cases. The CAA (+) cases of the older group had a longer duration of total fever (14.1 ± 10.4 vs 6.5 ± 1.9 days, p = 0.045), especially with respect to post-intravenous gamma globulin (IVGG) fever (7.9 ± 9.6 vs 1.1 ± 0.8 days, p = 0.052), and had higher total white blood cell counts, erythrocyte sedimentation rates, C-reactive protein levels, total bilirubin levels, and Harada scores and lower serum albumin and sodium levels than the CAA (−) cases. Multivariable logistic regression analysis revealed that the factors that were associated significantly with the development of CAA were the number of total symptoms (OR = 0.494, 95% confidence interval (CI) = 0.281–0.871, p = 0.015) in the younger group and the duration of post-IVGG fever (OR = 1.958, 95% CI = 1.098–3.492, p = 0.023) and the Harada score (OR = 3.455, 95% CI = 1.012–11.796, p = 0.048) in the older group.


Incomplete clinical manifestations in the younger group and IVGG nonresponsiveness in the older group are associated with the development of KD-associated CAA. These age-specific characteristics could aid the customization of the diagnostic and therapeutic strategies of KD, thereby helping to improve the outcome of this disease.


Kawasaki disease Coronary abnormalities Risk factor Age Incomplete manifestation Intravenous gamma globulin nonresponsiveness 



Kawasaki disease


intravenous gamma globulin


coronary artery abnormalities


C-reactive protein


erythrocyte sedimentation rate


B-type natriuretic peptide


Conflict of interest

We have no conflict of interest.


  1. 1.
    Anderson MS, Todd JK, Glode MP (2005) Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics 115(4):428–433 doi: 10.1542/peds.2004-1824 CrossRefGoogle Scholar
  2. 2.
    Belay ED, Maddox RA, Holman RC et al (2006) Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994–2003. Pediatr Infect Dis J 25(3):245–249 doi: 10.1097/01.inf.0000202068.30956.16 PubMedCrossRefGoogle Scholar
  3. 3.
    Burns JC, Glode MP (2004) Kawasaki syndrome. Lancet 364(9433):533–544 doi: 10.1016/S0140-6736(04)16814-1 PubMedCrossRefGoogle Scholar
  4. 4.
    Burns JC, Capparelli EV, Brown JA et al (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17(12):1144–1148 doi: 10.1097/00006454-199812000-00009 PubMedCrossRefGoogle Scholar
  5. 5.
    Chang FY, Hwang B, Chen SJ et al (2006) Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 25(3):241–244 doi: 10.1097/01.inf.0000202067.50975.90 PubMedCrossRefGoogle Scholar
  6. 6.
    Council on Cardiovascular Disease in the Young; Committee on Rheumatic Fever E, and Kawasaki Disease; American Heart Association (2001) Diagnostic guidelines for Kawasaki disease. Circulation 103(2):335–336Google Scholar
  7. 7.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D et al (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24(2):145–148 doi: 10.1007/s00246-002-0216-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Freeman AF, Shulman ST (2004) Refractory Kawasaki disease. Pediatr Infect Dis J 23(5):463–464 doi: 10.1097/01.inf.0000125893.66941.e0 PubMedCrossRefGoogle Scholar
  9. 9.
    Fukunishi M, Kikkawa M, Hamana K et al (2000) Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 137(2):172–176 doi: 10.1067/mpd.2000.104815 PubMedCrossRefGoogle Scholar
  10. 10.
    Genizi J, Miron D, Spiegel R et al (2003) Kawasaki disease in very young infants: high prevalence of atypical presentation and coronary arteritis. Clin Pediatr (Phila) 42(3):263–267 doi: 10.1177/000992280304200310 CrossRefGoogle Scholar
  11. 11.
    Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33(6):805–810PubMedGoogle Scholar
  12. 12.
    Honkanen VE, McCrindle BW, Laxer RM et al (2003) Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 24(2):122–126 doi: 10.1007/s00246-002-0063-1 PubMedCrossRefGoogle Scholar
  13. 13.
    Meddows-Taylor S, Tiemessen CT (2004) Age-related changes in polymorphonuclear neutrophil characteristics in infants born to human immunodeficiency virus type 1 seropositive mothers. Pediatr Allergy Immunol 15(2):172–182 doi: 10.1046/j.1399-3038.2003.00136.x PubMedCrossRefGoogle Scholar
  14. 14.
    Muta H, Ishii M, Sakaue T et al (2004) Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 114(3):751–754 doi: 10.1542/peds.2003-0118-F PubMedCrossRefGoogle Scholar
  15. 15.
    Muta H, Ishii M, Furui J et al (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95(2):189–193 doi: 10.1080/08035250500327328 PubMedCrossRefGoogle Scholar
  16. 16.
    Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110(17):2747–2771 doi: 10.1161/01.CIR.0000145143.19711.78 PubMedCrossRefGoogle Scholar
  17. 17.
    Popper SJ, Shimizu C, Shike H et al (2007) Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 8(12):R261 doi: 10.1186/gb-2007-8-12-r261 PubMedCrossRefGoogle Scholar
  18. 18.
    Research Committee on Kawasaki Disease (1984) Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, TokyoGoogle Scholar
  19. 19.
    Rosenfeld EA, Corydon KE, Shulman ST (1995) Kawasaki disease in infants less than one year of age. J Pediatr 126:524–529 doi: 10.1016/S0022-3476(95)70344-6 PubMedCrossRefGoogle Scholar
  20. 20.
    Rowley AH (2002) Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 21(6):563–565 doi: 10.1097/00006454-200206000-00015 PubMedCrossRefGoogle Scholar
  21. 21.
    Shulman ST, Rowley AH (2004) Advances in Kawasaki disease. Eur J Pediatr 163(6):285–291 doi: 10.1007/s00431-004-1431-z PubMedCrossRefGoogle Scholar
  22. 22.
    Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association (1992) Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. JAMA 268(15):2069–2073 doi: 10.1001/jama.268.15.2069 CrossRefGoogle Scholar
  23. 23.
    Stockheim JA, Innocentini N, Shulman ST (2000) Kawasaki disease in older children and adolescents. J Pediatr 137(2):250–252 doi: 10.1067/mpd.2000.105150 PubMedCrossRefGoogle Scholar
  24. 24.
    Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics 105(6):E78 doi: 10.1542/peds.105.6.e78 PubMedCrossRefGoogle Scholar
  25. 25.
    Witt MT, Minich LL, Bohnsack JF, Young PC (1999) Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 104(1):e10 doi: 10.1542/peds.104.1.e10 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • DooIl Song
    • 1
  • Yunku Yeo
    • 1
  • KeeSoo Ha
    • 1
  • GiYoung Jang
    • 1
  • JungHwa Lee
    • 1
    • 2
    Email author
  • KwangChul Lee
    • 1
  • ChangSung Son
    • 1
  • JooWon Lee
    • 1
  1. 1.Department of PediatricsKorea University College of MedicineSeoulSouth Korea
  2. 2.Department of PediatricsKorea University Medical CenterAnsanRepublic of Korea

Personalised recommendations